Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Comprehensive outcome research with safety data and practical protocol references
Peptide-based gut healing splits across four mechanistically distinct compounds acting on different layers of the gastrointestinal barrier. The animal dossier is extensive; the human evidence is sparse; the regulatory posture is sceptical. An honest map of what is known, what is guessed, and where the practical safety decisions actually are.
BPC-157 drives angiogenesis and tissue repair. Larazotide antagonises zonulin to re-seal tight junctions. KPV suppresses NF-κB-driven inflammation. LL-37 reinforces the antimicrobial and mucus defence. The mechanism map is coherent. The human trial record — Larazotide's discontinued Phase III, BPC-157's three small pilots, the FDA's Category 2 classification — is sobering. Grey-market sourcing, not the peptides themselves, is the dominant source of documented harm.
Detailed compound profiles with mechanisms, safety data, and dosing protocols
Evidence-based supplement stacks designed to support your peptide protocols
A naturally occurring tripeptide locked inside your collagen that modulates 4,192 human genes, acts as a safe copper chaperone, and signals systemic repair, with plasma levels dropping 60% between ages 20 and 60.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine) is a naturally occurring tripeptide embedded in Type I collagen. Liberated during tissue injury, it acts as a master repair signal modulating 4,192 human genes (roughly one-third of the genome). It drives collagen synthesis, delivers copper safely to enzymes like Superoxide Dismutase via a unique square-planar pyramid configuration, and shows emerging potential in gut barrier repair (SIRT1/STAT3) and COPD reversal (127-gene signature). Plasma levels decline 60% by age 60. Clinical protocols use a biphasic 30-day cycle (1mg escalating to 2mg) with a mandatory 30-day rest. FDA Category 2 restricts legal compounding for systemic use. Contraindicated in active malignancies and Wilson's Disease.
A synthetic heptapeptide that acts as a molecular GPS for your body's repair crew — directing cell migration, building new blood vessels into injured tissue, and potentially re-activating embryonic healing pathways.
TB-500 is the synthetic analog of Thymosin Beta-4, a naturally occurring protein involved in actin regulation, cell migration, and tissue repair. Its unique mechanism targets the body's internal repair logistics rather than just providing raw materials.
A 15-amino-acid gastric pentadecapeptide that coordinates multi-system repair through angiogenesis, collagen synthesis, and gut-brain axis stabilization.
BPC-157 is a synthetic peptide derived from human gastric juice, notable for its extreme biochemical stability and capacity to coordinate tissue repair across musculoskeletal, vascular, and neurological systems.
The biochemical cofactors your body needs to support TB-500 therapy.
Evidence-based supplement companion for TB-500 — a synthetic heptapeptide that acts as a molecular GPS for your body's repair crew — directing cell migration, building new blood vessels into injured tissue, and potentially re-activating embryonic healing pathways.
35+
Articles
18
Categories